Oncolytic Viruses as Antigen-Agnostic Cancer Vaccines

Alexander, 2016, The checkpoint immunotherapy revolution: what started as a trickle has become a flood, despite some daunting adverse effects; new drugs, indications, and combinations continue to emerge, P T, 41, 185 Alexandrov, 2013, Signatures of mutational processes in human cancer, Nature, 500, 415, 10.1038/nature12477 Alvarez-Breckenridge, 2015, Potentiating oncolytic viral therapy through an understanding of the initial immune responses to oncolytic viral infection, Curr. Opin. Virol., 13, 25, 10.1016/j.coviro.2015.03.015 Andtbacka, 2015, Talimogene laherparepvec improves durable response rate in patients with advanced melanoma, J. Clin. Oncol., 33, 2780, 10.1200/JCO.2014.58.3377 Andtbacka, 2016, Patterns of clinical response with talimogene laherparepvec (T-VEC) in patients with melanoma treated in the OPTiM phase III clinical trial, Ann. Surg. Oncol., 23, 4169, 10.1245/s10434-016-5286-0 Andtbacka, 2015, Final data from CALM: a phase II study of Coxsackievirus A21 (CVA21) oncolytic virus immunotherapy in patients with advanced melanoma, J. Clin. Oncol., 33, 10.1200/jco.2015.33.15_suppl.9030 Barber, 2005, VSV-tumor selective replication and protein translation, Oncogene, 24, 7710, 10.1038/sj.onc.1209042 Barber, 2011, Innate immune DNA sensing pathways: STING, AIMII and the regulation of interferon production and inflammatory responses, Curr. Opin. Immunol., 23, 10, 10.1016/j.coi.2010.12.015 Barber, 2015, STING: infection, inflammation and cancer, Nat. Rev. Immunol., 15, 760, 10.1038/nri3921 Bartee, 2017, In vivo and in situ programming of tumor immunity by combining oncolytics and PD-1 immune checkpoint blockade, Exp. Hematol. Oncol., 6, 15, 10.1186/s40164-017-0075-4 Bennett, 1999, Cutting edge: adenovirus E19 has two mechanisms for affecting class I MHC expression, J. Immunol., 162, 5049, 10.4049/jimmunol.162.9.5049 Brown, 2012, Eaten alive! Cell death by primary phagocytosis: 'phagoptosis', Trends Biochem. Sci., 37, 325, 10.1016/j.tibs.2012.05.002 Castello, 2011, The multifaceted poliovirus 2A protease: regulation of gene expression by picornavirus proteases, J. Biomed. Biotechnol., 2011, 369648 Chen, 2016, Regulation and function of the cGAS-STING pathway of cytosolic DNA sensing, Nat. Immunol., 17, 1142, 10.1038/ni.3558 Chesney, 2017, Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma, J. Clin. Oncol., 10.1200/JCO.2017.35.15_suppl.9509 Chiocca, 2014, Oncolytic viruses and their application to cancer immunotherapy, Cancer Immunol. Res., 2, 295, 10.1158/2326-6066.CIR-14-0015 Clemens, 2005, Translational control in virus-infected cells: models for cellular stress responses, Semin. Cell Dev. Biol., 16, 13, 10.1016/j.semcdb.2004.11.011 Corrales, 2017, Innate immune signaling and regulation in cancer immunotherapy, Cell Res., 27, 96, 10.1038/cr.2016.149 Dehne, 2017, Cancer cell and macrophage cross-talk in the tumor microenvironment, Curr. Opin. Pharmacol., 35, 12, 10.1016/j.coph.2017.04.007 Deng, 2014, STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors, Immunity, 41, 843, 10.1016/j.immuni.2014.10.019 Drappier, 2015, Inhibition of the OAS/RNase L pathway by viruses, Curr. Opin. Virol., 15, 19, 10.1016/j.coviro.2015.07.002 Durham, 2017, Oncolytic VSV primes differential responses to immuno-oncology therapy, Mol. Ther., 25, 1917, 10.1016/j.ymthe.2017.05.006 Elsedawy, 2013, Oncolytic vaccines, Expert Rev. Vaccines, 12, 1155, 10.1586/14760584.2013.836912 Engeland, 2014, CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy, Mol. Ther., 22, 1949, 10.1038/mt.2014.160 Farrington, 2013, Competition for antigen at the level of the APC is a major determinant of immunodominance during memory inflation in murine cytomegalovirus infection, J. Immunol., 190, 3410, 10.4049/jimmunol.1203151 Fernandes, 2016, Oncogenes: the passport for viral oncolysis through PKR inhibition, Biomark. Cancer, 8, 101, 10.4137/BIC.S33378 Finlay, 2006, Anti-immunology: evasion of the host immune system by bacterial and viral pathogens, Cell, 124, 767, 10.1016/j.cell.2006.01.034 Franz, 2017, Innate immune receptors as competitive determinants of cell fate, Mol. Cell, 66, 750, 10.1016/j.molcel.2017.05.009 Galanis, 2015, Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer, Cancer Res., 75, 22, 10.1158/0008-5472.CAN-14-2533 Gale, 1998, Molecular mechanisms of interferon resistance mediated by viral-directed inhibition of PKR, the interferon-induced protein kinase, Pharmacol. Ther., 78, 29, 10.1016/S0163-7258(97)00165-4 Galluzzi, 2017, Immunogenic cell death in cancer and infectious disease, Nat. Rev. Immunol., 17, 97, 10.1038/nri.2016.107 Galluzzi, 2018, Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018, Cell Death Differ., 25, 486, 10.1038/s41418-017-0012-4 Gao, 2009, Recombinant vesicular stomatitis virus targeted to Her2/neu combined with anti-CTLA4 antibody eliminates implanted mammary tumors, Cancer Gene Ther., 16, 44, 10.1038/cgt.2008.55 Gordon, 2017, PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity, Nature, 545, 495, 10.1038/nature22396 Guo, 2017, Oncolytic immunotherapy: conceptual evolution, current strategies, and future perspectives, Front. Immunol., 8, 555, 10.3389/fimmu.2017.00555 Gustin, 2003, Inhibition of nucleo-cytoplasmic trafficking by RNA viruses: targeting the nuclear pore complex, Virus Res., 95, 35, 10.1016/S0168-1702(03)00165-5 Harding, 2017, Mitotic progression following DNA damage enables pattern recognition within micronuclei, Nature, 548, 466, 10.1038/nature23470 Hardy, 1994, Herpes simplex virus inhibits host cell splicing, and regulatory protein ICP27 is required for this effect, J. Virol., 68, 7790, 10.1128/JVI.68.12.7790-7799.1994 Hewitt, 2003, The MHC class I antigen presentation pathway: strategies for viral immune evasion, Immunology, 110, 163, 10.1046/j.1365-2567.2003.01738.x Hill, 1995, Herpes simplex virus turns off the TAP to evade host immunity, Nature, 375, 411, 10.1038/375411a0 Hou, 2016, Oncolytic virus-mediated targeting of PGE2 in the tumor alters the immune status and sensitizes established and resistant tumors to immunotherapy, Cancer Cell, 30, 108, 10.1016/j.ccell.2016.05.012 Ichikawa, 2012, Epitope diversification driven by non-tumor epitope-specific Th1 and Th17 mediates potent antitumor reactivity, Vaccine, 30, 6190, 10.1016/j.vaccine.2012.07.060 Kaminskyy, 2010, To kill or be killed: how viruses interact with the cell death machinery, J. Intern. Med., 267, 473, 10.1111/j.1365-2796.2010.02222.x Kedl, 2003, Epitope dominance, competition and T cell affinity maturation, Curr. Opin. Immunol., 15, 120, 10.1016/S0952-7915(02)00009-2 Kedl, 2000, T cells compete for access to antigen-bearing antigen-presenting cells, J. Exp. Med., 192, 1105, 10.1084/jem.192.8.1105 Keller, 2016, Oncolytic viruses-immunotherapeutics on the rise, J. Mol. Med. (Berl.), 94, 979, 10.1007/s00109-016-1453-9 Kenney, 2015, Increased immune response variability during simultaneous viral coinfection leads to unpredictability in CD8 T cell immunity and pathogenesis, J. Virol., 89, 10786, 10.1128/JVI.01432-15 Kim, 2006, Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF, Mol. Ther., 14, 361, 10.1016/j.ymthe.2006.05.008 Knutson, 2005, Augmenting T helper cell immunity in cancer, Curr. Drug Targets Immune Endocr. Metabol. Disord., 5, 365, 10.2174/156800805774913006 Krysko, 2017, Necroptotic cell death in anti-cancer therapy, Immunol. Rev., 280, 207, 10.1111/imr.12583 Lichty, 2014, Going viral with cancer immunotherapy, Nat. Rev. Cancer, 14, 559, 10.1038/nrc3770 Liu, 2003, ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties, Gene Ther., 10, 292, 10.1038/sj.gt.3301885 Liu, 2014, Oncolytic vaccinia virotherapy for endometrial cancer, Gynecol. Oncol., 132, 722, 10.1016/j.ygyno.2014.01.009 Mackenzie, 2017, cGAS surveillance of micronuclei links genome instability to innate immunity, Nature, 548, 461, 10.1038/nature23449 Maroun, 2017, Designing and building oncolytic viruses, Future Virol., 12, 193, 10.2217/fvl-2016-0129 Mohme, 2017, Circulating and disseminated tumour cells - mechanisms of immune surveillance and escape, Nat. Rev. Clin. Oncol., 14, 155, 10.1038/nrclinonc.2016.144 Mohr, 2004, Neutralizing innate host defenses to control viral translation in HSV-1 infected cells, Int. Rev. Immunol., 23, 199, 10.1080/08830180490265600 Moresco, 2011, Toll-like receptors, Curr. Biol., 21, R488, 10.1016/j.cub.2011.05.039 Nagata, 2017, Programmed cell death and the immune system, Nat. Rev. Immunol., 17, 333, 10.1038/nri.2016.153 Naik, 2012, Curative one-shot systemic virotherapy in murine myeloma, Leukemia, 26, 1870, 10.1038/leu.2012.70 Obuchi, 2003, Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity, J. Virol., 77, 8843, 10.1128/JVI.77.16.8843-8856.2003 Puzanov, 2016, Talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma, J. Clin. Oncol., 34, 2619, 10.1200/JCO.2016.67.1529 Ribas, 2017, Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy, Cell, 170, 1109, 10.1016/j.cell.2017.08.027 Rivas, 2016, Shutoff of host gene expression in influenza a virus and herpesviruses: similar mechanisms and common themes, Viruses, 8, 102, 10.3390/v8040102 Ruotsalainen, 2015, Clonal variation in interferon response determines the outcome of oncolytic virotherapy in mouse CT26 colon carcinoma model, Gene Ther., 22, 65, 10.1038/gt.2014.83 Russell, 2014, Remission of disseminated cancer after systemic oncolytic virotherapy, Mayo Clin. Proc., 89, 926, 10.1016/j.mayocp.2014.04.003 Russell, 2017, Oncolytic virotherapy: a contest between apples and oranges, Mol. Ther., 25, 1107, 10.1016/j.ymthe.2017.03.026 Russell, 2012, Oncolytic virotherapy, Nat. Biotechnol., 30, 658, 10.1038/nbt.2287 Salama, 2017, Next steps in immuno-oncology: enhancing antitumor effects through appropriate patient selection and rationally designed combination strategies, Ann. Oncol., 28, 57, 10.1093/annonc/mdw534 Samson, 2018, Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade, Sci. Transl. Med., 10, 10.1126/scitranslmed.aam7577 Schiavoni, 2013, Type I interferons as stimulators of DC-mediated cross-priming: impact on anti-tumor response, Front. Immunol., 4, 483, 10.3389/fimmu.2013.00483 Schock, 2017, Induction of necroptotic cell death by viral activation of the RIG-I or STING pathway, Cell Death Differ., 24, 615, 10.1038/cdd.2016.153 Schumacher, 2015, Neoantigens in cancer immunotherapy, Science, 348, 69, 10.1126/science.aaa4971 Shen, 2016, Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia, Blood, 127, 1449, 10.1182/blood-2015-06-652503 Takeuchi, 2009, Innate immunity to virus infection, Immunol. Rev., 227, 75, 10.1111/j.1600-065X.2008.00737.x Toda, 2015, Clearance of apoptotic cells and pyrenocytes, Curr. Top. Dev. Biol., 114, 267, 10.1016/bs.ctdb.2015.07.017 Topalian, 2015, Immune checkpoint blockade: a common denominator approach to cancer therapy, Cancer Cell, 27, 450, 10.1016/j.ccell.2015.03.001 Vyas, 2008, The known unknowns of antigen processing and presentation, Nat. Rev. Immunol., 8, 607, 10.1038/nri2368 Woller, 2015, Viral infection of tumors overcomes resistance to PD-1-immunotherapy by broadening neoantigenome-directed T-cell responses, Mol. Ther., 23, 1630, 10.1038/mt.2015.115 Woo, 2015, Innate immune recognition of cancer, Annu. Rev. Immunol., 33, 445, 10.1146/annurev-immunol-032414-112043 Xia, 2016, Recurrent loss of STING signaling in melanoma correlates with susceptibility to viral oncolysis, Cancer Res., 76, 6747, 10.1158/0008-5472.CAN-16-1404